Dexamethasone punctal plug - Ocular Therapeutix

Drug Profile

Dexamethasone punctal plug - Ocular Therapeutix

Alternative Names: Dexamethasone intracanalicular plug; Dexamethasone punctum plug; Dextenza; OTX-DP

Latest Information Update: 18 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ocular Therapeutix
  • Class Anti-inflammatories; Antiemetics; Antineoplastics; Fluorinated steroids; Glucocorticoids; Pregnadienetriols; Small molecules
  • Mechanism of Action Glucocorticoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Ocular pain
  • Phase III Allergic conjunctivitis; Ocular inflammation
  • Phase II Dry eyes

Most Recent Events

  • 07 Nov 2017 Ocular Therapeutix announces intention to resubmit NDA to US FDA for Ocular pain in the first half of 2018
  • 12 Jul 2017 US FDA denies NDA of dexamethasone punctal plug for treatment of Ocular pain in USA
  • 11 Jul 2017 Ocular Therapeutics receives complete response letter from the FDA for Dexamethasone punctal plug in Ocular pain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top